ClinicalTrials.gg
Status unknownNCT02908438Updated Sep 21, 2016

Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles

A Phase 1 interventional study of Gonadotrophin releasing hormone agonist(GnRHa) in GnRHa;LPS, sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. Status unknown. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2016-09-21.

Sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Study summary

The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.

02

Conditions studied

  • GnRHa;LPS
03

In context

Lead sponsor

Northwest Women's and Children's Hospital, Xi'an, Shaanxi is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age \< 37 years;
  2. One or more high quality embryos have been got in IVF/ICSI treatment;
  3. To transfer at lest 2 fresh embryos;
  4. Uterine endometrial thickness ≥ 7mm;
  5. Patients have signed informed consents.

Exclusion criteria

Exclusion Criteria:

  1. ≥3 IVF/ICSI/FET cycles and no pregnancy;
  2. Polycystic ovary syndrome(PCOS);
  3. uterine malformation;
  4. endometriosis
  5. patients with a history of recurrent pregnancy loss.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    GnRHa group

    Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.

    Drug: Gonadotrophin releasing hormone agonist(GnRHa)

  • No intervention
    control group

    Control group receive only the routine LPS.

Interventions

  • DrugGonadotrophin releasing hormone agonist(GnRHa)

    GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.

06

What researchers measure

Primary outcomes

  1. pregnancy rate

    Time frame: up to 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016 and a primary completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2016
First posted
Sep 21, 2016
Start
Sep 2016
Primary completionEst.
Sep 2017
Last update
Sep 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02908438
Lead sponsor
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Responsible party
Sponsor
First posted
Sep 21, 2016
Start date
Sep 2016
Primary completion
Sep 2017 (estimated)
Last update
Sep 21, 2016

Study contacts

Shan Liu, PHD
Contact
123564787@qq.com
86+18991932450
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion